Update on atopic dermatitis: Insights into pathogenesis and new treatment paradigms

Allergy and Asthma Proceedings

Volumn 25, Issue 5, 2004, Pages 279-282

  Boguniewicz, Mark ^a,b  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b Children's Hospital Colorado   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CATHELICIDIN; CORTICOSTEROID; DEFENSIN; FLUTICASONE PROPIONATE; MOMETASONE FUROATE; PIMECROLIMUS;

ALLERGY; ASTHMA; ATOPIC DERMATITIS; DRUG EFFICACY; DRUG SAFETY; HUMAN; PATHOGENESIS; PROTEIN SECRETION; RELAPSE; REVIEW; SKIN ATROPHY; SKIN INFLAMMATION; STAPHYLOCOCCUS AUREUS;

ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; CALCINEURIN; DERMATITIS, ATOPIC; HUMANS; STAPHYLOCOCCUS AUREUS;

EID: 8844269103     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Boguniewicz M, ed. Atopic dermatitis. Immunol Allergy Clinics N Am 22:1-178, 2002.
2. Williams H, Robertson C, Stewart A, et al. Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. J Allergy Clin Immunol 103:125-138, 1999.
3. Laughter D, Istvan JA, Tofte SJ, et al. The prevalence of atopic dermatitis in Oregon schoolchildren. J Am Acad Dermatol 43:649-655, 2000.
4. Gehring U, Bolte G, Borte M, et al. Exposure to endotoxin decreases the risk of atopic eczema in infancy: A cohort study. J Allergy Clin Immunol 108:847-854, 2001.
5. Björkstén B, Sepp E, Julge K, et al. Allergy development and the intestinal microflora during the first year of life. J Allergy Clin Immunol 18:516-520, 2001.
6. Lawson V, Lewis-Jones MS, Finlay AY, et al. The family impact of childhood atopic dermatitis: The Dermatitis Family Impact Questionnaire. Br J Dermatol 138:107-113, 1998.
7. Bender BG, Leung SB, Leung DY. Actigraphy assessment of sleep disturbance in patients with atopic dermatitis: An objective life quality measure. J Allergy Clin Immunol 111:598-602, 2003.
8. Ellis CN, Drake LA, Prendergast MM, et al. Cost of atopic dermatitis and eczema in the United States. J Am Acad Dermatol 46:361-370, 2002.
9. Lau S, Nickel R, Niggemann B, et al. The development of childhood asthma: Lessons from the German Multicentre Allergy Study (MAS). Paed Resp Reviews 3:265-272, 2002.
10. Sicherer SH, Sampson HA. Food hypersensitivity and atopic dermatitis: Pathophysiology, epidemiology, diagnosis, and management. J Allergy Clin Immunol 104:S114-S122, 1999.
11. Schafer T, Heinrich J, Wjst M, et al. Association between severity of atopic eczema and degree of sensitization to aeroallergens in schoolchildren. J Allergy Clin Immunol 104:1280-1284, 1999.
12. Kinaciyan T, Natter S, Kraft D, et al. IgE autoantibodies monitored in a patient with atopic dermatitis under cyclosporin A treatment reflect tissue damage. J Allergy Clin Immunol 109:717-719, 2002.
13. Leyden JE, Marples RR, Kligman AM. Staphylococcus aureus in the lesions of atopic dermatitis. Br J Dermatol 90:525-530, 1974.
14. Boguniewicz M, Sampson H, Leung S, et al. Effects of cefuroxime axetil on Staphylococcus aureus colonization and superantigen production in atopic dermatitis. J Allergy Clin Immunol 108:651-652, 2001.
15. Williams J, Vowels B, Honig P, et al. S. aureus isolation from the lesions, the hands, and the anterior nares of patients with atopic dermatitis. Pediatr Dermatol 15:194-198, 1998.
16. Cho S-H, Strickland I, Boguniewicz M, et al. Fibronectin and fibrinogen contributes to the enhanced binding of S. aureus to atopic skin. J Allergy Clin Immunol 108:269-274, 2001.
17. Arikawa J, Ishibashi M, Kawashima M, et al. Decreased levels of sphingosine, a natural antimicrobial agent, may be associated with vulnerability of the stratum corneum from patients with atopic dermatitis to colonization by Staphylococcus aureus. J Invest Dermatol 119:433-439, 2002.
18. Stalder JF, Fleury M, Sourisse M, et al. Local steroid therapy and bacterial skin flora in atopic dermatitis. Br J Dermatol 131:536-540, 1994.
19. Remitz A, Kyllonen H, Granlund H, et al. Tacrolimus ointment reduces staphylococcal colonization of atopic dermatitis lesions. J Allergy Clin Immunol 107:196-197, 2001.
20. Bunikowski R, Mielke M, Skarabis H, et al. Prevalence and role of serum IgE antibodies to the Staphylococcus aureus-derived superantigens SEA and SEB in children with atopic dermatitis. J Allergy Clin Immunol 103:119-124, 1999.
21. Nomura I, Tanaka K, Tomita H, et al. Evaluation of the staphylococcal exotoxins and their specific IgE in childhood atopic dermatitis. J Allergy Clin Immunol 104:441-446, 1999.
22. Boguniewicz M, Sampson H, Harbeck R, et al. Effects of cefuroxime axetil on S. aureus colonization and superantigen production in atopic dermatitis. J Allergy Clin Immunol 108:651-652, 2001.
23. Strickland I, Hauk PJ, Trumble AE, et al. Evidence for superantigen involvement in skin homing of T cells in atopic dermatitis. J Invest Dermatol 112:249-253, 1999.
24. Leung DYM, Harbeck R, Bina P, et al. Presence of IgE antibodies to staphylococcal exotoxins on the skin of patients with atopic dermatitis: Evidence for a new group of allergens. J Clin Invest 92:1374-1380, 1993.
25. Hofer MF, Harbeck RJ, Schlievert PM, et al. Staphylococcal toxins augment specific IgE responses by atopic patients exposed to allergen. J Invest Dermatol 112:171-176, 1999.
26. Hauk PJ, Hamid QA, Chrousos GP, et al. Induction of corticosteroid insensitivity in human PBMCs by microbial superantigens. J Allergy Clin Immunol 105:782-787, 2000.
27. Strange P, Skov L, Lisby S, et al. Staphylococcal enterotoxin B applied on intact normal and intact atopic skin induces dermatitis. Arch Dermatol 132:27-33, 1996.
28. Skov L, Olsen JV, Giorno R, et al. Application of staphylococcal enterotoxin B on normal and atopic skin induces upregulation of T cells via a superantigen-mediated mechanism. J Allergy Clin Immunol 105:820-826, 2000.
29. Medzhitov R, Janeway C Jr. Innate immunity. N Engl J Med 343: 338-344, 2000.
30. Gallo RL, Murakami M, Ohtake T, et al. Biology and clinical relevance of naturally occurring antimicrobial peptides. J Allergy Clin Immunol 110:823-831, 2002.
31. Nizet V, Ohtake T, Lauth X, et al. Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature 414:454-457, 2001.
32. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 415:389-395, 2002.
33. Gallo RL, Ono M, Povsic T, et al. Syndecans, cell surface heparan sulfate proteoglycans, are induced by a proline-rich antimicrobial peptide from wounds. Proc Natl Acad Sci USA 91:11035-11039, 1994.
34. Frohm M, Agerberth B, Ahangari G, et al. The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders. J Biol Chem 272:15258-15263, 1997.
35. Ong PY, Ohtake T, Brandt C, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 347: 1151-1160, 2002.
36. Engler RJM, Kenner J, Leung DYM. Smallpox vaccination: Risk considerations for patients with atopic dermatitis. J Allergy Clin Immunol 110:357-365, 2002.
37. Wolkerstorfer A, Strobos MA, Glazenburg EJ, et al. Fluticasone propionate 0.05% cream once daily versus clobetasone butyrate 0.05% cream twice daily in children with atopic dermatitis. J Am Acad Dermatol 39:226-231, 1998.
38. Lebwohl M. A comparison of once-daily application of mometasone furoate 0.1% cream compared with twice-daily hydrocortisone valerate 0.2% cream in pediatric atopic dermatitis patients who failed to respond to hydrocortisone: Mometasone Furoate Study Group. Int J Dermatol 38:604-606, 1999.
39. Friedlander SF, Hebert AA, Allen DB. Fluticasone Pediatrics Safety Study Group. Safety of fluticasone propionate cream 0.05% for the treatment of severe and extensive atopic dermatitis in children as young as 3 months. J Am Acad Dermatol 46:387-393, 2002.
40. Van Der Meer JB, Glazenburg EJ, Mulder PG, et al. The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. The Netherlands Adult Atopic Dermatitis Study Group. Br J Dermatol 140:1114-1121, 1999.
41. Hanifin J, Gupta AK, Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol 147:528-537, 2002.
42. Berth-Jones J, Damstra RJ, Golsch S, et al. Multinational Study Group. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: Randomised, double blind, parallel group study. Br Med J 326:1367-1372, 2003.
43. Boguniewicz M. Combination therapy and new directions for managing atopic dermatitis. Allergy Asthma Proc 23:243-246, 2002.
44. Kapp A, Papp K, Bingham A, et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid antiinflammatory drug. J Allergy Clin Immunol 110:277-284, 2002.
45. Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 110:e2, 2002.
46. Meurer M, Folster-Holst R, Wozel G, et al. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: A six-month study. Dermatology 205:271-277, 2002.
47. Ho VC, Gupta A, Kaufmann R, et al. Safety and efficacy of non-steroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr 142:155-162, 2003.